journal article·2025-10-01

Cas9 Protein Outperforms mRNA in Lipid Nanoparticle-Mediated CFTR Repair

Ryann A. Joseph, Rebecca M. Haley, Marshall S. Padilla, Adele S. Ricciardi, Hannah M. Yamagata, Michael J. Mitchell

Nano Letters· Volume 25· Issue 39
Publisher page

Abstract

Lipid nanoparticles (LNPs) are currently one of the most clinically advanced delivery systems for nucleic acid cargo and hold great potential for clinical applications in gene editing and the treatment of genetic diseases. LNP-mediated delivery of Cas9 with single guide RNA (sgRNA) and homology-directed repair DNA template (ssDNA) enables efficient and precise editing in vitro and in vivo . Comparative analysis of LNP delivery of Cas9 as protein or mRNA for relevant clinical targets, such as cystic fibrosis (CF), which is caused by mutations in the CFTR gene, is imperative in the design of corrective therapeutics for genetic diseases. Here, we show that delivery of Cas9 protein LNPs outperforms Cas9 mRNA LNPs when evaluated for in vivo lung editing as well as corrective CRISPR/Cas9 editing and functional recovery of the CFTR protein. These results demonstrate the ability to optimize the use of CRISPR/Cas9 LNPs for cystic fibrosis applications.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: CRISPR and Genetic Engineering · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering

University of Pennsylvania

Center for Fetal Research, Division of General, Thoracic, and Fetal Surgery

Children’s Hospital of Philadelphia

Penn Institute for RNA Innovation

Abramson Cancer Center

Perelman School of Medicine

Institute for Immunology

Cardiovascular Institute

Funding

National Science Foundation Graduate Research Fellowship Program · University of Pennsylvania · National Institute of Dental and Craniofacial Research · Center for Undergraduate Research and Fellowships, University of Pennsylvania · Cystic Fibrosis Foundation · American Cancer Society · Division of Chemical, Bioengineering, Environmental, and Transport Systems · Burroughs Wellcome Fund · National Institutes of Health

References (27)

Show source-provided references
1. 10.1038/nrdp.2015.1010.1038/nrdp.2015.10 ↗
2. 10.1126/science.257046010.1126/science.2570460 ↗
3. 10.1080/17476348.2019.163454710.1080/17476348.2019.1634547 ↗
4. 10.3390/ijms2111390310.3390/ijms21113903 ↗
5. 10.1089/biores.2012.021810.1089/biores.2012.0218 ↗
6. 10.1038/s41587-019-0050-110.1038/s41587-019-0050-1 ↗
7. 10.1073/pnas.040193310110.1073/pnas.0401933101 ↗
8. 10.1016/j.stem.2013.11.00210.1016/j.stem.2013.11.002 ↗
9. 10.1016/j.addr.2022.11411310.1016/j.addr.2022.114113 ↗
10. 10.1038/s41587-024-02437-310.1038/s41587-024-02437-3 ↗
11. 10.1021/acs.molpharmaceut.1c0091610.1021/acs.molpharmaceut.1c00916 ↗
12. 10.1016/j.ymthe.2018.05.01410.1016/j.ymthe.2018.05.014 ↗
13. 10.1038/s41467-023-42948-210.1038/s41467-023-42948-2 ↗
14. 10.1016/j.ejpb.2024.11420710.1016/j.ejpb.2024.114207 ↗
15. 10.1016/j.omtn.2024.10217210.1016/j.omtn.2024.102172 ↗
16. 10.1021/acsami.3c0150110.1021/acsami.3c01501 ↗
17. 10.1038/s41467-020-17029-310.1038/s41467-020-17029-3 ↗
18. 10.1002/jbm.a.3770510.1002/jbm.a.37705 ↗
19. 10.1021/acs.nanolett.1c0135310.1021/acs.nanolett.1c01353 ↗
20. 10.1038/nbt.347110.1038/nbt.3471 ↗
21. 10.1021/acsnano.4c1661710.1021/acsnano.4c16617 ↗
22. 10.1016/j.ymthe.2025.01.03710.1016/j.ymthe.2025.01.037 ↗
23. 10.1080/14712598.2021.186920810.1080/14712598.2021.1869208 ↗
24. 10.1165/ajrcmb.10.1.750734210.1165/ajrcmb.10.1.7507342 ↗
25. 10.1074/jbc.M110.14080610.1074/jbc.M110.140806 ↗
26. 10.7554/eLife.0476610.7554/eLife.04766 ↗
27. 10.1038/nbt.262310.1038/nbt.2623 ↗